Drug FDA Class II Ongoing cGMP deviation
Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18
Ascend Laboratories, LLC Published Jul 23, 2025
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 60/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Ascend Laboratories, LLC or your place of purchase with questions, and see the source record below for full details.
Reason for recall
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Hazards
N-nitroso-dimethyl-rizatriptan · primary
Affected products (1)
Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18
RIZATRIPTAN BENZOATE · N/A
NDC: 67877-261, 67877-262, 67877-261-30, 67877-261-01, 67877-261-05, 67877-261-18, 67877-261-25, 67877-262-30, 67877-262-01, 67877-262-05, 67877-262-18, 67877-262-25
Lot codes: 23142117, 24142625
Code info: Lot 23142117, 23142119, 23142122, Exp Date: May 2026; Lot 24142625, Exp Date: Jun. 2027
Affected areas
Nationwide
Timeline
- InitiatedJul 9, 2025
- PublishedJul 23, 2025
- Recall number
- D-0533-2025
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.